Burchert et al. demonstrated that the treatment with imatinib of BCR/ABL-positive LAMA-84 cells and primary leukemia cells in vitro, and in a patient with CP-CML in vivo, it activated the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway [116]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.